Treatment Patterns and Survival Outcomes Among Androgen ...

In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment ...

Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.

Treatment patterns and outcomes in patients with nonmetastatic ...

Results: Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as ...

Real-world treatment patterns and progression-free survival among ...

However, sequential ARPI use appeared to provide diminishing returns, with a PFS of <4 months seen at 2L in those who had received 1L ARPIs. Treatment outcomes ...

Real-World Clinical Outcomes and Treatment Patterns Among Black ...

Apalutamide is an androgen receptor signaling inhibitor that, in combination with androgen deprivation therapy (ADT), was approved for the ...

Treatment Patterns and Survival Outcomes Among Androgen ...

Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer.

Treatment patterns and overall survival outcomes among patients ...

ADT = androgen deprivation therapy; NCCN = National Comprehensive Cancer Network; RT = radiation therapy. EUROPEAN UROLOGY OPEN SCIENCE 37 (2022) ...

Real-world treatment patterns and overall survival among men with ...

These include chemotherapy (docetaxel and cabazitaxel), immunotherapy (sipuleucel-T), novel hormonal therapy (abiraterone and enzalutamide), ...

Treatment patterns and oncological outcomes of older adults with ...

Rates of local prostate cancer treatment differed significantly between all three groups (p < 0.01). Regarding mHSPC treatment, androgen ...

A US real-world study of treatment patterns and outcomes in ...

Real-world claims and EHR data show that survival among men with LPC/LAPC differs by primary treatment and time point of disease recurrence thereafter.

Treatment Patterns and Clinical Outcomes Among Patients With ...

Novel hormonal therapy and taxane chemotherapy were most commonly used in 1L; taxane use increased in later lines. Median overall survival (95% confidence ...

Treatment patterns for patients with BRCA1/2-positive metastatic ...

The top 3 treatment regimens in 1L, overall, were ADT monotherapy (19%), enzalutamide (14%), and olaparib (13%). The main reason for censoring ...

Treatment patterns and survival in metastatic castration‐sensitive ...

Patients were categorized into four cohorts: ADT-only (± <90-day nonsteroidal anti-androgen [NSAA] use), ADT + NSAA, ADT + docetaxel, and ADT + ...

Treatment patterns and outcomes in metastatic castration-resistant ...

In the BRCA subgroup, 64.6% of patients received ARSi as 1L treatment for mCRPC, compared with 59.7% of patients in the non-BRCA subgroup (Table ...

Abstract 930: Treatment patterns and overall survival among men ...

Compared to 1L, the proportion of patients receiving NHTs was lower in 2L (33%) and 3L (17%), while the proportion of patients receiving taxanes ...

Treatment patterns and outcomes for metastatic castration-resistant ...

In the first-line (1L) setting, abiraterone (Abi, 37%) was the most-prescribed therapy, followed by enzalutamide (Enza, 28%) and docetaxel (15%) ...

Treatment Patterns and Outcomes in Patients With Metastatic ...

Abiraterone/prednisone and enzalutamide accounted for 65% of first-line therapies and 54% of second-line therapies. Docetaxel was the most ...

Treatment Patterns and Overall Survival Outcomes Among Patients ...

Overall Survival · Survival Outcomes · High-grade Prostate Cancer · Treatment Patterns · Aged 80 Years and over · Androgen Deprivation Therapy · Radiation Therapy ...

to Sixth- line Metastatic Castration-resistant Prostate Cancer ...

Significant changes in treatment patterns could be observed for mHSPC and mCRPC patients within the past decade, and usage of ADT monotherapy ...

Real-World Treatment Patterns Among Patients With Metastatic ...

For patients who received a taxane chemotherapy (16%; n = 98; mainly docetaxel), the most common first-line mCRPC treatments were abiraterone ( ...